8-K
filed November 7, 2024, 6:59 PM ET
ticker NKTR
CIK 0000906709
other material
confidence high
sentiment neutral
materiality 0.70
Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M
NEKTAR THERAPEUTICS
- Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.
- Cash & investments $249M as of Sep 30; expected to fund operations into Q4 2026.
- Definitive agreement to sell Huntsville PEGylation business to Ampersand for $90M ($70M cash + $20M equity).
- R&D expense rose to $35.0M from $24.1M, driven by rezpegaldesleukin and NKTR-0165 development.
- Topline data for rezpegaldesleukin Phase 2b in atopic dermatitis expected H1 2025; alopecia areata H2 2025.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-24-095423
- form_type
- 8-K
- ticker
- NKTR
- cik
- 0000906709
- company_name
- NEKTAR THERAPEUTICS
- filed_at
- 2024-11-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:11.338650+00:00
- generated_at
- 2026-05-30T04:11:38.455107+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-24-095423
- json_url
- https://secwatch.observer/filing/0001213900-24-095423.json
- markdown_url
- https://secwatch.observer/filing/0001213900-24-095423.md
- text_url
- https://secwatch.observer/filing/0001213900-24-095423.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/906709/000121390024095423/0001213900-24-095423-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/906709/000121390024095423/ea0220296-8k_nektar.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
MVIS
MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026
MICROVISION, INC.
June 1, 2026, 5:02 PM ET
other_material
Items 8.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
LOKV
Live Oak enters Forward Purchase Agreement to back Teamshares merger, up to 4M shares at ~$10.54
Live Oak Acquisition Corp. V
June 1, 2026, 5:00 PM ET
other_material
Items 1.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
AIB
Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline
BlockchAIn Digital Infrastructure, Inc.
June 1, 2026, 4:57 PM ET
other_material
Items 1.01, 7.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
VDTA
Vertical Data launches Vertical Edge, a direct-ownership edge data center platform
Vertical Data Inc.
June 1, 2026, 4:47 PM ET
other_material
Items 8.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
AII
American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit
American Integrity Insurance Group, Inc.
June 1, 2026, 4:31 PM ET
other_material
Items 7.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
XAIR
Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026
Beyond Air, Inc.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CTOR
Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer
CITIUS ONCOLOGY, INC.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CSR
Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City
CENTERSPACE
June 1, 2026, 4:30 PM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.